Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 163-171

  Bowden, Nikola A ^a,b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Carboplatin; Cisplatin; ERCC1; NSCLCs; Nucleotide excision repair; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; HELICASE; IRINOTECAN; MESSENGER RNA; NAVELBINE; NUCLEASE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; REPLICATION FACTOR A; UNCLASSIFIED DRUG; VORINOSTAT; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XPB PROTEIN; XPF PROTEIN; XPG PROTEIN; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COLON CANCER; COLORECTAL CANCER; DNA DAMAGE; DNA DENATURATION; DRUG CYTOTOXICITY; EXCISION REPAIR; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH TUMOR; TESTIS CANCER; XERODERMA PIGMENTOSUM; CLINICAL TRIAL (TOPIC); DNA REPAIR; GENETICS; NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS;

EID: 84896122888     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.005     Document Type: Review

References (99)

1. Aroroa S., Kothandapani A., Tillison K., Kalman-Maltese V., Patrick S.M. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair 2010, 9:745-753.
2. Rosell R., Taron M., Barnadas A., Scagliotti G., Sarries C., Roig B. Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer. Cancer Control 2003, 10:297-305.
3. Zamble D.B., Lippard S.J. Cisplatin and DNA-repair in cancer-chemotherapy. Trends Biochem. Sci. 1995, 20:435-439.
4. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 1998, 24:331-344.
5. Rosenberg B., VanCamp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385-386.
6. Reed E. ERCC1 measurements in clinical oncology. N. Engl. J. Med. 2006, 355:1054-1055.
7. Almeida G.M., Duarte T.L., Farmer P.B., Steward W.P., Jones G.D. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int. J. Cancer 2008, 122:1810-1819.
8. Welsh C., Day R., McGurk C., Masters J.R.W., Wood R.D., Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer 2004, 110:352-361.
9. Johnson S.W., Swiggard P.A., Handel L.M., Brennan J.M., Godwin A.K., Ozols R.F., Hamilton T.C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res. 1994, 54:5911-5916.
10. Zeng-Rong N., Paterson J., Alpert L., Tsao M.S., Viallet J., Alaoui-Jamali M.A. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res. 1995, 55:4760-4764.
11. Wang L.E., Yin M., Dong Q., Stewart D.J., Merriman K.W., Amos C.I., Spitz M.R., Wei Q. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J. Clin. Oncol. 2011, 29:4121-4128.
12. Siddik Z.H. Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. The Cancer Handbook 2002, 1295-1313. Nature Publishing Group, London. M. Alison (Ed.).
13. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 1994, 269:787-790.
14. Hansson J., Wood R.D. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum (II). Nucleic Acids Res. 1989, 17:8073-8091.
15. Hansson J., Grossman L., Lindahl T., Wood R.D. Complementation of the xeroderma pigmentosum DNA repair synthesis defect with Escherichia coli UvrABC proteins in a cell-free system. Nucleic Acids Res. 1990, 18:35-40.
16. Friedberg E.C. How nucleotide excision repair protects against cancer. Nat. Rev. Cancer 2001, 1:22-33.
17. Hess M.T., Naegeli H., Capobianco M. Stereoselectivity of human nucleotide excision repair promoted by defective hybridization. J. Biol. Chem. 1998, 273:27867-27872.
18. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
19. Nouspikel T. DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell. Mol. Life Sci. 2009, 66:994-1009.
20. Budden T., Bowden N.A. The role of altered nucleotide excision repair and UVB-induced DNA damage in melanoma genesis. Int. J. Mol. Sci. 2013, 14:1132-1151.
21. Cleaver J.E., Lam E.T., Revet I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat. Rev. Genet. 2009, 10:756-768.
22. Aboussekhra A., Biggerstaff M., Shivji M.K.K., Vilpo J.A., Moncollin V., Podust V.N., Protic M., Hubscher U., Egly J.-M., Wood R.D. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995, 80:859-868.
23. Marini F., Nardo T., Giannattasio M., Minuzzo M., Stefanini M., Plevani P., Falconi M.M. DNA nucleotide excision repair-dependant signaling to checkpoint activation. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17325-17330.
24. Tornaletti S. Transcription-coupled DNA repair: directing your effort where it's most needed. Cell. Mol. Life Sci. 2009, 66:1010-1020.
25. Conforti G., Nardo T., D'Incalci M., Stefanini M. Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation. Oncogene 2000, 19:2714-2720.
26. Ljungman M., Lane D.P. Transcription - guarding the genome by sensing DNA damage. Nat. Rev. Cancer 2004, 4:727-737.
27. van den Boom V., Jaspers N.G., Vermeulen M. When machines get stuck - obstructed RNA polymerase II: displacement, degradation or suicide. BioEssays 2002, 24:780-784.
28. Yamaizumi M., Sugano T. UV-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes independent of the cell cycle. Oncogene 1994, 9:2775-2784.
29. Kraemer K.H. Sunlight and skin cancer: another link revealed. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:11-14.
30. Bootsma D., Kraemer K.H., Cleaver J.E., Hoeijmakers J.H.J. Nucleotide excision repair syndromes: xeroderma pigmentosum and trichothiodystrophy. The genetic basis of human cancer 1998, 245-274. McGraw-Hill. B. Vogelstein, K.W. Kinzler (Eds.).
31. Bowden N.A., Ashton K.A., Avery-Kiejda K.A., Zhang X.D., Hersey P., Scott R.J. Nucleotide excision repair gene expression after cisplation treatment in melanoma. Cancer Res. 2010, 70:7905-7917.
32. Bowden N.A., Ashton K.A., Vilain R.E., Braye S.G., Avery-Kiejda K.A., Davey R., Murray H.C., Budden T., Zhang X.D., Hersey P., Scott R.J. Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma. PLoS One 2013, 8:e70424.
33. Barckhausen C., Roos W.P., Naumann S.C., Kaina B. Malignant melanoma cells acquire resistance to DNA interstrandcross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair. Oncogene 2013, (Advance online publication April 2013).
34. Sugasawa K. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. Mutat. Res. 2010, 685:29-37.
35. Sugasawa K., Ng J.M.Y., Masutani C., Iwai S., van der Spek P.J., Eker A.P.M., Hanaoka F., Bootsma D., Hoeijmakers J.H. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol. Cell 1998, 2:223-232.
36. Fitch M.E., Cross I.V., Turner S.J., Adimoolam S., Lin C.X., Williams K.G., Ford J.M. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient fibroblasts. DNA Repair 2003, 2:819-826.
37. Moser J., Volker M., Kool H., Alekseev S., Vrieling H., Yasui A., Van Zeeland A.A., Mullenders L.H.F. The UV-damaged DNA binding protein mediates efficient targeting of the nucleotide excision repair complex to UV-induced photo lesions. DNA Repair 2005, 4:571-582.
38. Wang Q.E., Zhu Q., Wani G., Chen J., Wani A.A. UV radiation-induced XPC translocation within chromatin is mediated by damaged-DNA binding protein DDB2. Carcinogenesis 2004, 25:571-582.
39. Chen Z., Yang J., Wang G., Song B., Li J., Xu Z. Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression. Cancer Res. 2007, 67:4578-4585.
40. Wang G., Chuang L., Zhang X.X., Colton S., Dombowski A., Reiners J., Diakiw A., Xu X.S. The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation. Nucleic Acids Res. 2004, 32:2231-2240.
41. Wang G., Dombowski A., Chuang L., Xu X.S. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response. Cell Res. 2004, 14:303-314.
42. Barakat B.M., Wang Q.E., Han C., Milum K., Yin D.T., Zhao Q., Wani G., Arafa E.S., El-Mahdy M.A., Wani A.A. Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis. Int. J. Cancer 2010, 127:977-988.
43. Stoyanova T., Roy N., Kopanja D., Bagchi S., Raychaudhuri P. DDB2 decides cell fate following DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10690-10695.
44. Schwertman P., Lagarou A., Dekkers D.H.W., Raams A., van der Hoek A.C., Laffeber C., Hoejimakers J.H.J., Demmers J.A.A., Fousteri M., Vermeulen W., Marteijn J. UV-sensitive syndrome protein UVSSA recruits USP7 to regulate transcription-coupled repair. Nat. Genet. 2012, 44:598-602.
45. Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., Varela I., Lin M., Ordonez G.R., Bignell G.R., Ye K., Alipaz J., Bauer M.J., Beare D., Butler A., Carter R.J., Chen L., Cox A.J., Edkins S., Kokko-Gonzales P.I., Gormley N.A., Grocock R.J., Haudenschild C.D., Hims M.M., James T., Jia M., Kingsbury Z., Leroy C., Marshall J., Menzies A., Mudie L.J., Ning Z., Royce T., Schulz-Trieglaff O.B., Spiridou A., Stebbings L.A., Szajkowski L., Teague J., Williamson D., Chin L., Ross M.T., Campbell P.J., Bentley D.R., Futreal P.A., Stratton M.R. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
46. Pleasance E.D., Stephens P.J., O'Meara S., McBride D.J., Meynert A., Jones D., Lin M.L., Beare D., Lau K.W., Greenman C., Varela I., Nik-Zainal S., Davies H.R., Ordonez G.R., Mudie L.J., Latimer C., Edkins S., Stebbings L., Chen L., Jia M., Leroy C., Marshall J., Menzies A., Butler A., Teague J.W., Mangion J., Sun Y.A., McLaughlin S.F., Peckham H.E., Tsung E.F., Costa G.L., Lee C.C., Minna J.D., Gazdar A., Birney E., Rhodes M.D., McKernan K.J., Stratton M.R., Futreal P.A., Campbell P.J. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
47. L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A. Aparicio, S. Behjati, A.V. Biankin, G.R. Bignell, N. Bolli, A. Borg, A.L. Børresen-Dale, S. Boyault, B. Burkhardt, A.P. Butler, C. Caldas, H.R. Davies, C. Desmedt, R. Eils, J.E. Eyfjörd, J.A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinski, N. Jäger, D.T. Jones, D. Jones, S. Knappskog, M. Kool, S.R. Lakhani, C. López-Otín, S. Martin, N.C. Munshi, H. Nakamura, P.A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J.V. Pearson, X.S. Puente, K. Raine, M. Ramakrishna, A.L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T.N. Schumacher, P.N. Span, J.W. Teague, Y. Totoki, A.N. Tutt, R. Valdés-Mas, M.M. van Buuren, L. van 't Veer, A. Vincent-Salomon, N. Waddell, L.R. Yates, Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, J. Zucman-Rossi, P.A. Futreal, U. McDermott, P. Lichter, M. Meyerson, S.M. Grimmond, R. Siebert, E. Campo, T. Shibata, S.M. Pfister, P.J. Campbell, M.R. Stratton, Signatures of mutational processes in human cancer. Nature 500 (2013).
48. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002, 62:4899-4902.
49. Lu Y., Mani S., Kandimalla E.R., Yu D., Agrawal S., States J.C., Bregman D.B. The Cockayne syndrome group B DNA repair protein as an anti-cancer target. Int. J. Oncol. 2001, 19:1089-1097.
50. McKay B.C., Becerril C., Ljungman M. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 2001, 20:6805-6808.
51. Weaver D.A., Crawford E.L., Warner K.A., Elkhairi F., Khuder S.A., Willey J.C. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer 2005, 4.
52. Aloyz R., Xu Z.-Y., Bello V., Bergeron J., Han F.-Y., Yan Y., Malapetsa A., Alaoui-Jamali M.A., Duncan A.M.V., Panasci L. Regulation of cisplatin resistance and homologous recombinatorial repair by the TFIIH subunit XPD. Cancer Res. 2002, 62:5457-5462.
53. Plasencia C., Martinez-Balibrea E., Martinez-Cardus A., Quinn D.I., Abad A., Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int. J. Oncol. 2006, 29:225-235.
54. Khrunin A.V., Moisseev A., Gorbunova V., Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010, 10:54-61.
55. Bradbury P.A., Kulke M.H., Heist R.S., Zhou W., Ma C., Xu W., Marshall A.L., Zhai R., Hooshmand S.M., Asomaning K., Su L., Shepard F.A., Lynch T.J., Wain J.C., Christiani D.C., Liu G. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet. Genomics 2009, 19:613-625.
56. Avan A., Pacetti P., Reni M., Milella M., Vasile E., Mambrini A., Vaccaro V., Caponi S., Cereda S., Peters G.J., Cantore M., Giovannetti E. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys741Gln polymorphism strikes back. Int. J. Cancer 2013, 133:1016-1022.
57. Rosell R., Taron M., Camps C., Lopez-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today 2003, 39:775-786.
58. Li F., Sun X., Sun N., Qin S., Cheng H., Feng J., Chen B., Cheng L., Lu Z., Ji J., Zhou Y. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 2010, 33:489-494.
59. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., Di Marsico R., Antonuzzo A., Orlandini C., Ricciardi S., Del Tacca M., Peters G.J., Falcone A., Danesi R. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 2008, 14:1797-1803.
60. Giachino D.F., Ghio P., Regazzoni S., Mandrile G., Novello S., Sevelaggi G., Gregori D., DeMarchi M., Scagliotti G.V. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin. Cancer Res. 2007, 13:2876-2881.
61. Cleaver J.E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat. Rev. Cancer 2005, 5:564-573.
62. Dunkern T.R., Fritz G., Kaina B. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucelotide excision repair. Mutat. Res. 2001, 486:249-258.
63. Lee K.B., Parker R.J., Bohr V., Cornelison T., Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993, 14:2177-2180.
64. Stevens E.V., Nishizuka S., Antony S., Reimers M., Varma S., Young L., Munson P.J., Weinstein J.N., Kohn E.C., Pommier Y. Predicting cisplatin and trabectedin drug sensitivity. Mol. Cancer Ther. 2008, 7:10-18.
65. Taverna P., Hansson J., Scanlon K.J., Hill B.T. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 1994, 15:2053-2056.
66. Zhao R., Rabo Y.B., Egyhazi S., Andersson A., Edgren M.R., Linder S., Hansson J. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Anticancer Drugs 1995, 6:657-668.
67. Dabholker M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer. J. Natl. Cancer Inst. 1992, 84:1512-1517.
68. Dabholker M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 1994, 94:703-708.
69. Stevens E.V., Raffeld M., Espina V., Kristensen G.B., Trope C.G., Kohn E.C., Davidson B. Expression of xeroderma pigmentosum A proteins predicts improved outcome in metastatic ovarian carcinoma. Cancer 2005, 103:2313-2319.
70. Feng J., Sun X., Sun N., Qin S., Li F., Cheng H., Chen B., Cao Y., Ma J., Cheng L., Lu Z., Ji J., Zhou Y. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim. Biophys. Sin. 2009, 41:429-435.
71. Kang T.-H., Lindsey-Boltz L.A., Reardon J.T., Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HER2 ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4890-4895.
72. Wold M.S., Kelly T. Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. Annu. Rev. Biochem. 1997, 66:61-92.
73. Patrick S.M., Tillison K., Horn J.M. Recognition of cisplatin-DNA interstrand cross-links by replication protein A. Biochemistry (Mosc) 2008, 47:10188-10196.
74. Manthey K.C., Glanzer J.G., Dimitrova D.D., Oakley G.G. Hyperphosphorylation of replication protein A in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines. Head Neck 2010, 32:636-645.
75. Damia G., Imperatori L., Stefanini M., D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int. J. Cancer 1996, 66:779-783.
76. Arnould S., Hennebelle I., Canal P., Bugat R., Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer 2003, 39:112-119.
77. Chang I.-Y., Kim M.-H., Kim H.B., Lee D.Y., Kim S.-Y., Kim H.-Y., You H.J. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem. Biophys. Res. Commun. 2005, 327:225-233.
78. Lord R.V.N., Brabender J., Gandara D., Alberola V., Camps C., Domine M., Cardenal F., Sanchez J.M., Gumerlock P.H., Taron M., Sanchez J.J., Danenberg K.D., Danenberg P.V., Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8:2286-2291.
79. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., Itoh K., Yamada A., Aizawa H. Excision repair cross-complementing group 1 predicts progression-free overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007, 98:1336-1343.
80. Tiseo M., Bordi P., Bortesi B., Boni L., Boni C., Baldini E., Grossi F., Recchia F., Zanelli F., Fontanini G., Naldi N., Campanini N., Azzoni C., Bordi C., Ardizzoni A. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC. Brit. J. Cancer 2013, 108:1695-1703.
81. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med. 2004, 350:351-360.
82. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad M., Taranchon E., Filipits M., Pirker R., Popper H.H., Stahel R., Sabatier L., Pignon J.P., Tursz T., Le Chevalier T., Soria J.C., Investigators I.B. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355:983-991.
83. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 2000, 60:1305-1313.
84. S. De Dosso, E. Zanellato, M. Nucifora, R. Boldorini, A. Sonzogni, R. Biffi, N. Fazio, E. Bucci, O. Beretta, S. Crippa, P. Saletti, M. Frattini, ERCC1 predicts outcome in patients with gastric cancer treated with adjuvent cisplatin-based chemotherapy. Cancer Chemother. Pharmacol. (2013) (Epub ahead of print).
85. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., Groshen S., Salonga D., Cohen H., Laine L., Crookes P., Silberman H., Baranda J., Konda B., Leichman L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 1998, 16:309-316.
86. Viguier J., Boige V., Miquel C., Pocard M., Giraudeau B., Sabourin J.-C., Ducreux M., Sarasin A., Praz F. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 2005, 11:6212-6217.
87. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., Lopez-Vivanco G., Camps C., Botia M., Nunez L., Sanchez-Ronco M., Sanchez J.J., Lopez-Brea M., Barneto I., Paredes A., Medina B., Artal A., Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 2004, 15:1194-1203.
88. De Silva I.U., McHugh P.J., Clingen P.H., Hartley J.A. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res. 2002, 30:3848-3856.
89. Sun X., Li F., Sun N., Shukui Q., Baoan C., Jifeng F., Lu C., Zuhong L., Hongyan C., YuanDong C., Jiazhong J., Yingfeng Z. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009, 65:230-236.
90. Chen S., Zhang J., Wang R., Luo X., Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010, 70.
91. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., Vinolas N., Paz-Ares L., Lopez-Vivanco G., Munoz M.A., Felip E., Alberola V., Camps C., Domine M., Sanchez J.J., Sanchez-Ronco M., Danenberg K., Taron M., Gandara D., Rosell R. Customizing cisplatin based on quantitative excision repair cross-complimenting 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:2747-2754.
92. Simon G., Sharma A., Li X., Hazelton T., Walsh F., Williams C., Chiappori A., Haura E., Tanvetyanon T., Antonia S., Cantor A., Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:2741-2746.
93. Reynolds C., Obasaju C., Schell M.J., Li X., Zheng Z., Boulware D., Caton J.R., DeMarco L.C., O'Rourke M.A., Wright G.S., Boehm K.A., Asmar L., Bromund J., Peng G., Monberg M.J., Bepler G. Randomized phase III trials of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:5808-5815.
94. Bepler G., Williams C., Schell M.J., Chen W., Zheng Z., Simon G., Gadgeel S., Zhao X., Schreiber F., Brahmer J., Chiappori A., Tanvetyanon T., Pinder-Schenck M., Gray J., Haura E., Antonia S., Fischer J.R. Randomizes international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2013, 31:2404-2412.
95. Friboulet L., Olaussen K.A., Pignon J.P., Shepard F.A., Tsao M.S., Graziano S., Kratzke R., Douillard J.Y., Seymour L., Pirker R., Filipits M., Andre F., Solary E., Ponsonnailles F., Robin A., Stoclin A., Dorvault N., Commo F., Adam J., Vanhecke E., Saulnier P., Thomale J., Le Chevalier T., Dunant A., Rousseau V., Le Teuff G., Brambilla E., Soria J.C. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N. Engl. J. Med. 2013, 368:1101-1110.
96. Fan L., Niu Y., Zhang S., Shi L., Guo H., Liu Y., Zhang R. Development of a screening system for DNA damage and repair of potential carcinogens based on dual luciferase assay in human HepG2 cell. Mutagenesis 2013, 28:515-524.
97. Mendez P., Taron M., Moran T., Fernandez M.A., Requena G., Rosell R. A modified host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes. DNA Repair 2011, 10:603-610.
98. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33:9-23.
99. Song L., Ritchie A.-M., McNeil E.M., Li W., Melton D.W. Identification of DNA repair gene Ercc1 as a novel target in melanoma. Pigm. Cell Melanoma Res. 2011, 24:966-971.